🧬 Apolipoprotein M (ApoM) is emerging as a key regulator of vascular biology.

ApoM, an HDL-associated lipocalin, transports sphingosine-1-phosphate (S1P) and selectively activates S1PR1 signaling in endothelial cells.

This pathway stabilizes the endothelial barrier, promotes nitric-oxide mediated vasodilation, and suppresses vascular inflammation.

Clinical studies increasingly link lower ApoM levels with cardiometabolic disease, CKD, and heart failure risk.

New therapies—including ApoM-fusion biologics and selective S1PR1 agonists—may harness this pathway for vascular protection.

The ApoM–S1P axis may represent a new frontier in precision cardiovascular medicine.